DAE HWA PHARM CO., LTD
067080 | KO
Overview
Corporate Details
- ISIN(s):
- KR7067080002
- LEI:
- Country:
- South Korea
- Address:
- 강원도 횡성군 횡성읍 한우로 495, 횡성군
- Website:
- http://www.dhpharm.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 34.5 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-08-11 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.7 MB | ||
| 2025-08-06 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
|
Korean | 8.3 KB | ||
| 2025-08-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-22 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-06-12 00:00 |
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.4 KB | ||
| 2025-06-12 00:00 |
Related Party Transaction
[기재정정]타인에대한채무보증결정
|
Korean | 24.3 KB | ||
| 2025-06-12 00:00 |
Capital/Financing Update
[기재정정]타인에대한담보제공결정
|
Korean | 25.9 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (리포락셀액(파클리탁셀)의 품목허가사항 변경신청 (유방암 신규 적응증 추가를 위한 식품의약품안전…
|
Korean | 16.5 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB |
Automate Your Workflow. Get a real-time feed of all DAE HWA PHARM CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAE HWA PHARM CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAE HWA PHARM CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
United States of America
ACXP
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
United States of America
ADAP
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
South Korea
179530
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
United States of America
ADCT
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
Switzerland
ADXN
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
United States of America
ADIL
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
United States of America
ACET
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
United States of America
ANL
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
United States of America
ADMA
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
United States of America
ADVM